Clinical usefulness of PI3K/Akt/mTOR genotyping in companion with other clinical variables in metastatic renal cell carcinoma patients treated with everolimus in the second and subsequent lines.

Bodnar, L

Clinical usefulness of PI3K/Akt/mTOR genotyping in companion with other clinical variables in metastatic renal cell carcinoma patients treated with everolimus in the second and subsequent lines. [electronic resource] - Annals of oncology : official journal of the European Society for Medical Oncology Jul 2015 - 1385-9 p. digital

Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't

1569-8041

10.1093/annonc/mdv166 doi


Adult
Aged
Carcinoma, Papillary--drug therapy
Carcinoma, Renal Cell--drug therapy
Class I Phosphatidylinositol 3-Kinases
Everolimus--therapeutic use
Female
Follow-Up Studies
Genotype
Humans
Kidney Neoplasms--drug therapy
Male
Middle Aged
Mutation--genetics
Neoplasm Grading
Phosphatidylinositol 3-Kinases--genetics
Phosphoinositide-3 Kinase Inhibitors
Polymerase Chain Reaction
Prognosis
Prospective Studies
Protein Kinase Inhibitors--therapeutic use
Survival Rate
TOR Serine-Threonine Kinases--antagonists & inhibitors